Literature DB >> 3741715

The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.

D Bach, R Blevins, N Kerner, M Rubenfire, D J Edwards.   

Abstract

The effect of verapamil pre-treatment on the pharmacokinetics and metabolism of antipyrine was studied in eight healthy male volunteers. The oral clearance of antipyrine was decreased from 2.18 to 1.95 l h-1 (P less than 0.01) by verapamil (80 mg three times daily for 2 days prior to antipyrine administration and 2 days following) while half-life was increased from 13.2 to 15.6 h (P less than 0.01). The urinary excretion of norantipyrine, 4-hydroxyantipyrine and 3-hydroxymethylantipyrine was decreased by 19.2%, 23.1% and 16.7% respectively (P less than 0.05) in the presence of verapamil. In addition, the rate constants for formation of each of these metabolites were significantly decreased by an average of approximately 30%. These results suggest that verapamil is capable of inhibiting oxidative metabolism, a finding which could be of clinical significance for drugs highly dependent upon pathways such as those inhibited in this study for elimination.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3741715      PMCID: PMC1400979          DOI: 10.1111/j.1365-2125.1986.tb05230.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.

Authors:  M Eichelbaum; A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Effects of metoprolol and propranolol on theophylline elimination.

Authors:  K A Conrad; D W Nyman
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

4.  Kinetic considerations relating to the accrual and elimination of drug metabolites.

Authors:  A J Cummings; B K Martin; G S Park
Journal:  Br J Pharmacol Chemother       Date:  1967-02

5.  Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.

Authors:  N D Bax; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

6.  Direct measurement of propranolol bioavailability during accumulation to steady-state.

Authors:  A J Wood; K Carr; R E Vestal; S Belcher; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

7.  The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects.

Authors:  T K Daneshmend; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Reduced verapamil clearance during long-term oral administration.

Authors:  D G Shand; S C Hammill; L Aanonsen; E L Pritchett
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

9.  Verapamil kinetics in normal subjects and patients with coronary artery spasm.

Authors:  S B Freedman; D R Richmond; J J Ashley; D T Kelly
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

10.  Verapamil disposition kinetics in chronic atrial fibrillation.

Authors:  R E Kates; D L Keefe; J Schwartz; S Harapat; E B Kirsten; D C Harrison
Journal:  Clin Pharmacol Ther       Date:  1981-07       Impact factor: 6.875

View more
  8 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

3.  Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.

Authors:  D O Rumiantsev; V K Piotrovskii; V I Metelitsa; I D Slastnikova; E V Kokurina
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

4.  The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.

Authors:  J C McCourty; J H Silas; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

6.  Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers.

Authors:  G I Adebayo; A Akintonwa; A F Mabadeje
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Dextromethorphan pretreatment induces antipyrine clearance in the rat.

Authors:  C K Svensson; J A Ware
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

Review 8.  Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.

Authors:  R Donnelly; G J Macphee
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.